Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in ...